IMU.AX
Price:
$0.043
Market Cap:
$319.85M
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research ...[Read more]
Industry
Biotechnology
IPO Date
1998-12-31
Stock Exchange
ASX
Ticker
IMU.AX
According to Imugene Limited’s latest financial reports and current stock price. The company's current ROE is -95.62%. This represents a change of 211.09% compared to the average of -30.74% of the last 4 quarters.
The mean historical ROE of Imugene Limited over the last ten years is -36.21%. The current -95.62% ROE has changed 164.09% with respect to the historical average. Over the past ten years (40 quarters), IMU.AX's ROE was at its highest in in the June 2009 quarter at 3.05%. The ROE was at its lowest in in the June 2012 quarter at -72.98%.
Average
-36.21%
Median
-27.84%
Minimum
-126.58%
Maximum
-17.57%
Discovering the peaks and valleys of Imugene Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 533.05%
Maximum Annual ROE = -17.57%
Minimum Annual Increase = -38.32%
Minimum Annual ROE = -126.58%
Year | ROE | Change |
---|---|---|
2024 | -126.58% | 533.05% |
2023 | -19.99% | -26.77% |
2022 | -27.30% | -3.82% |
2021 | -28.39% | 61.55% |
2020 | -17.57% | -38.32% |
2019 | -28.49% | 12.07% |
2018 | -25.42% | 15.55% |
2017 | -22.00% | -36.71% |
2016 | -34.76% | 10.10% |
2015 | -31.57% | 0.44% |
The current ROE of Imugene Limited (IMU.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-57.96%
5-year avg
-43.97%
10-year avg
-36.21%
Imugene Limited’s ROE is greater than BrainChip Holdings Ltd (-142.45%), greater than Mesoblast Limited (-17.79%), greater than Lake Resources NL (-35.77%), greater than Immutep Limited (-34.61%), less than PolyNovo Limited (7.45%),
Company | ROE | Market cap |
---|---|---|
-142.45% | $658.29M | |
-17.79% | $3.22B | |
-35.77% | $69.49M | |
-34.61% | $473.07M | |
7.45% | $1.44B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Imugene Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Imugene Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Imugene Limited's ROE?
How is the ROE calculated for Imugene Limited (IMU.AX)?
What is the highest ROE for Imugene Limited (IMU.AX)?
What is the 3-year average ROE for Imugene Limited (IMU.AX)?
What is the 5-year average ROE for Imugene Limited (IMU.AX)?
How does the current ROE for Imugene Limited (IMU.AX) compare to its historical average?